Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)
| Autor: | Jiao, Deng, Wei, Jiang, Liang, Liu, Wenli, Zhan, Yudi, Wu, Xiangshang, Xu |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Oncology Letters. 25 |
| ISSN: | 1792-1082 1792-1074 |
| Popis: | Programmed death ligand 1 (PD-L1) is widely expressed in human tumors. It is widely known for its immunosuppressive function as it can help tumor cells evade T cell immune killing through the PD-1/PD-L1 signal. A number of clinical trials have proved that the destruction of the combination of PD-1 and PD-L1 by antibodies could significantly affect patients with advanced cancer. However, a number of patients with cancer still cannot benefit from PD-1/PD-L1 blocking therapy. The main reason is that PD-L1 also has some intrinsic regulatory functions to promote the progression of tumors. PD-L1 Protein contains an intrinsic domain that could link to other signal pathways, but the mechanism has not yet been fully revealed. The present review mainly discussed the non-immune checkpoint functions of PD-L1, such as its role in regulating cell proliferation, cell metabolism, drug resistance and maintaining epithelial-mesenchymal transition and stemness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|